Spruce Biosciences Q2 net loss widens on higher expenses
SPRB•Analyst coverage
Spruce said the current average analyst rating on the shares is buy, with 8 strong buy or buy recommendations, no hold ratings, and no sell or strong sell ratings.
Wall Street's median 12-month price target for Spruce Biosciences, Inc. is $145.00, about 212.4% above its August 11 closing price of $46.41.
TA-ERT timeline and funding
The company expects to submit a BLA for TA-ERT in Q4 2026 and to initiate the TrAnsform confirmatory study in Q4 2026.
Spruce also said it received a $5.5 million strategic investment from the Cure Sanfilippo Foundation and the National MPS Society to partially fund the TA-ERT expanded access program. The company said cash and equivalents are expected to fund operations into the second half of 2027.
Q2 loss widens as expenses rise
Spruce Biosciences said its second-quarter net loss widened as operating expenses increased to advance TA-ERT.
The company reported a Q2 loss per share of $6.68 and a net loss of . Income from operations was , and operating expenses were .
